secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001714899-24-000031
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics outlines 2024 pipeline milestones, plans to spin out preclinical small molecule portfolio
--------------------------------------------------------------------------------

- Cash of ~$1.12B as of Sep 30, 2023; expects 2024 OpEx ≤2023, extending runway into 2027.
- Plans to complete enrollment in late-stage MPS II (COMPASS) and ALS (HEALEY) trials in 2024.
- DNL593 (PTV:PGRN) Phase 1/2 paused for protocol modifications after infusion-related reactions in 2 participants.
- Announces spin-out of preclinical small molecule portfolio into a separately funded NewCo.
- IND-enabling studies for OTV:MAPT (Alzheimer's) and OTV:SNCA (Parkinson's) expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000031/0001714899-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000031/dnli-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer